Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

2.

Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.

Monegal A, Guañabens N, Suárez MJ, Suárez F, Clemente G, García-González M, De la Mata M, Serrano T, Casafont F, Tome S, Barrios C, Navasa M.

Transpl Int. 2009 Feb;22(2):198-206. doi: 10.1111/j.1432-2277.2008.00763.x. Epub 2008 Sep 15. Erratum in: Transpl Int. 2009 Jun;22(6):679. Torne, Santiago [corrected to Tome, Santiago].

3.

Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.

Reeves HL, Francis RM, Manas DM, Hudson M, Day CP.

Liver Transpl Surg. 1998 Sep;4(5):404-9.

4.

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS.

N Engl J Med. 2001 Sep 27;345(13):948-55.

5.

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.

Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC.

J Bone Miner Res. 2005 Jun;20(6):977-86. Epub 2005 Jan 18.

6.

Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.

Cauza E, Etemad M, Winkler F, Hanusch-Enserer U, Partsch G, Noske H, Dunky A.

J Clin Pharm Ther. 2004 Oct;29(5):431-6. Erratum in: J Clin Pharm Ther. 2005 Feb;30(1):96. Hanusch-Enserer, H [corrected to Hanusch-Enserer, U].

PMID:
15482386
7.

Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.

Walsh SB, Altmann P, Pattison J, Wilkie M, Yaqoob MM, Dudley C, Cockwell P, Sweny P, Banks LM, Hall-Craggs M, Noonan K, Andrews C, Cunningham J.

Am J Kidney Dis. 2009 May;53(5):856-65. doi: 10.1053/j.ajkd.2008.11.036.

PMID:
19393473
8.

Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial.

Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP.

Calcif Tissue Int. 1997 Oct;61(4):266-71.

PMID:
9312195
9.

Bone densitometry in pediatric patients treated with pamidronate.

Grissom LE, Kecskemethy HH, Bachrach SJ, McKay C, Harcke HT.

Pediatr Radiol. 2005 May;35(5):511-7. Epub 2005 Jan 18.

PMID:
15655696
10.

Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation.

Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE.

J Hepatol. 2002 Jul;37(1):93-100.

PMID:
12076867
11.

The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.

Vis M, Bultink IE, Dijkmans BA, Lems WF.

Osteoporos Int. 2005 Nov;16(11):1432-5. Epub 2005 May 10.

PMID:
15883662
12.

Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.

Palomba S, Orio F Jr, Manguso F, Falbo A, Russo T, Tolino A, Tauchmanovà L, Colao A, Doldo P, Mastrantonio P, Zullo F.

Osteoporos Int. 2005 Sep;16(9):1141-9. Epub 2005 Jun 1.

PMID:
15928801
14.

Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.

Land C, Rauch F, Travers R, Glorieux FH.

Bone. 2007 Mar;40(3):638-44. Epub 2006 Nov 28.

PMID:
17127117
15.

Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis.

Haworth CS, Selby PL, Adams JE, Mawer EB, Horrocks AW, Webb AK.

Thorax. 2001 Apr;56(4):314-6.

16.

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH.

Osteoporos Int. 2005 May;16(5):510-6. Epub 2004 Aug 18.

PMID:
15322742
17.
18.

Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial.

Koeberle D, Bacchus L, Thuerlimann B, Senn HJ.

Support Care Cancer. 1999 Jan;7(1):21-7.

PMID:
9926970
19.

The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.

Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N, Santiago HT, Bober M.

Calcif Tissue Int. 2003 Feb;72(2):103-12. Epub 2002 Dec 4.

PMID:
12457260
20.

Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study.

Armingeat T, Brondino R, Pham T, Legré V, Lafforgue P.

Osteoporos Int. 2006;17(11):1659-65. Epub 2006 Aug 8.

PMID:
16896508

Supplemental Content

Support Center